Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)

Next Previous
X
Search
Trial Profile

A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Pemetrexed (Primary) ; Trastuzumab-deruxtecan (Primary) ; Volrustomig (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms DL03
  • Sponsors AstraZeneca

    • Most Recent Events

    • 03 Sep 2024 According to an AstraZeneca media release, at WCLC 2024, an oral presentation will highlight efficacy and safety data from Part 1 of the DESTINY-Lung03 Phase Ib trial.
    • 27 Aug 2024 Planned number of patients changed from 248 to 244.
    • 05 Jun 2024 Planned number of patients changed from 168 to 248.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top